Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Aristotle Atlantic Core Equity Strategy 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Aristotle Atlantic Core Equity Strategy)

Primary Source Intelligence • Q2 2024 Letter Analysis

Aristotle Atlantic Core Equity Strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Aristotle Atlantic Core Equity Strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+14.22%

Digest Analysis

Quick Take

"Aristotle Atlantic outperformed in Q2 2024 driven by AI beneficiaries Nvidia and Alphabet, plus strong healthcare selections."

Executive Summary

Aristotle Atlantic's Core Equity strategy outperformed the S&P 500 in Q2 2024, returning 5.51% net versus 4.28% for the index. The portfolio benefited from strong security selection in Information Technology and Healthcare, driven primarily by AI-related investments and medical device companies. Key contributors included Nvidia, which continued to see accelerating demand for GPU semiconductors from hyperscalers and enterprises building AI computing infrastructure, and Alphabet, which reported strong earnings across all business segments while maintaining search market leadership despite GenAI competition. The manager added three new positions during the quarter: Amphenol, Boston Scientific, and Microchip Technology, all positioned to benefit from secular trends in AI data centers, aging demographics, and industrial IoT recovery respectively. While equity valuations remain elevated and geopolitical uncertainty persists, the strategy maintains focus on company-level fundamentals and secular growth drivers. The manager expects potential market volatility ahead but remains constructive on companies with strong product cycles and technological advantages.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The manager demonstrates moderate-high conviction through detailed thesis explanations for new positions, specific catalyst identification, and clear rationale for sells. Named positions with sizing context and multi-year outlooks for key holdings like Amphenol and Boston Scientific support this score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges positive earnings growth and potential rate cuts but balances this with concerns about high valuations, geopolitical uncertainty, and slowing economic activity. The outlook is cautiously constructive rather than bullish.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The portfolio added three new positions during the quarter and maintained focus on growth themes like AI and healthcare, indicating moderate risk appetite. However, the manager also sold three positions, suggesting selective rather than aggressive positioning.

Capital Deployment

0%

De-riskingDeploying

De-risking (0%)

The portfolio activity shows rotation rather than net deployment, with three buys and three sells during the quarter. No cash level changes are mentioned, indicating balanced capital allocation without directional bias.

Forward Guidance

10%

CautiousExpansionary

Cautious (10%)

The manager expects potential higher volatility and acknowledges many unresolved issues, while maintaining a company-level focus. The guidance is cautious with no clear deployment bias, emphasizing selectivity and patience.

Language Signal

15%

BearishBullish

Bearish (15%)

Language is balanced with mentions of opportunities in AI and secular trends offset by risk language around high valuations, geopolitical uncertainty, and potential volatility. Slightly more cautious than bullish overall.

Perceived Risk

65%

Low RiskElevated

Elevated Risk (65%)

The manager identifies multiple specific risks including high equity valuations, geopolitical uncertainty, U.S. election concerns, slowing economic activity, and stagflation risks. These are discussed with meaningful detail rather than brief mentions.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

The manager sees selective opportunities in defined areas like AI beneficiaries, healthcare demographics, and industrial recovery, but emphasizes the need for selectivity given high valuations. Opportunities exist but require careful selection.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The strategy demonstrates multi-year thinking with references to Boston Scientific's 2024-2026 plan, Amphenol's multi-year AI buildout thesis, and focus on secular tailwinds. The approach is patient capital with 2-5 year thesis horizons for key positions.